WO2000004899A1 - Ophthalmic compositions for treating ocular hypertension - Google Patents
Ophthalmic compositions for treating ocular hypertension Download PDFInfo
- Publication number
- WO2000004899A1 WO2000004899A1 PCT/US1999/016374 US9916374W WO0004899A1 WO 2000004899 A1 WO2000004899 A1 WO 2000004899A1 US 9916374 W US9916374 W US 9916374W WO 0004899 A1 WO0004899 A1 WO 0004899A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- prostaglandin
- carbonic anhydrase
- ophthalmologically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU51144/99A AU5114499A (en) | 1998-07-21 | 1999-07-20 | Ophthalmic compositions for treating ocular hypertension |
CA002337349A CA2337349A1 (en) | 1998-07-21 | 1999-07-20 | Ophthalmic compositions for treating ocular hypertension |
JP2000560892A JP2002521333A (en) | 1998-07-21 | 1999-07-20 | Ophthalmic composition for the treatment of high intraocular pressure |
EP99935726A EP1100491A1 (en) | 1998-07-21 | 1999-07-20 | Ophthalmic compositions for treating ocular hypertension |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11995198A | 1998-07-21 | 1998-07-21 | |
US09/119,951 | 1998-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000004899A1 true WO2000004899A1 (en) | 2000-02-03 |
Family
ID=22387375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/016374 WO2000004899A1 (en) | 1998-07-21 | 1999-07-20 | Ophthalmic compositions for treating ocular hypertension |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1100491A1 (en) |
JP (1) | JP2002521333A (en) |
AU (1) | AU5114499A (en) |
CA (1) | CA2337349A1 (en) |
WO (1) | WO2000004899A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6264935B1 (en) * | 1996-10-17 | 2001-07-24 | Laboratoires Msd - Chibret | Ophthalmic composition containing a carbonic anhydrase inhibitor and xanthan gum |
WO2001085169A2 (en) * | 2000-05-10 | 2001-11-15 | Alcon, Inc. | R-eliprodil for treating glaucoma |
JP2004528369A (en) * | 2001-05-03 | 2004-09-16 | アラーガン、インコーポレイテッド | Compositions with improved pharmacokinetic properties |
WO2005110424A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Biodegradable intraocular implants containing prostamides |
US7875271B2 (en) | 2006-03-23 | 2011-01-25 | Senju Pharmaceutical Co., Ltd. | Ophthalmic composition comprising xanthan gum and glucose |
US7939511B2 (en) | 2004-09-28 | 2011-05-10 | Senju Pharmaceutical Co., Ltd. | Ophthalmic composition containing xanthan gum and amino acid |
US7998942B2 (en) | 2005-07-11 | 2011-08-16 | Senju Pharamaceutical Co., Ltd. | Eye drop preparation comprising xanthan gum and terpenoid |
USRE43372E1 (en) | 1999-03-05 | 2012-05-08 | Duke University | C16 unsaturated FP-selective prostaglandins analogs |
US8906962B2 (en) | 2000-03-31 | 2014-12-09 | Duke University | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
US9101583B2 (en) | 2004-04-30 | 2015-08-11 | Allergan, Inc. | Microparticles manufactured in an oil-in-water process comprising a prostamide |
US9326949B2 (en) | 2004-04-30 | 2016-05-03 | Allergan, Inc. | Method of making oil-in-oil emulsified polymeric implants containing a hypotensive lipid |
US9346837B2 (en) | 2000-03-31 | 2016-05-24 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US9775846B2 (en) | 2004-04-30 | 2017-10-03 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2423711B (en) * | 2005-10-24 | 2007-02-14 | Fortune Apex Dev Ltd | Method for preparing a pharmaceutical composition with enhanced mucoadhesion |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811443A (en) * | 1992-10-13 | 1998-09-22 | Alcon Laboratories, Inc. | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma |
-
1999
- 1999-07-20 JP JP2000560892A patent/JP2002521333A/en not_active Withdrawn
- 1999-07-20 CA CA002337349A patent/CA2337349A1/en not_active Abandoned
- 1999-07-20 EP EP99935726A patent/EP1100491A1/en not_active Withdrawn
- 1999-07-20 WO PCT/US1999/016374 patent/WO2000004899A1/en not_active Application Discontinuation
- 1999-07-20 AU AU51144/99A patent/AU5114499A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811443A (en) * | 1992-10-13 | 1998-09-22 | Alcon Laboratories, Inc. | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6264935B1 (en) * | 1996-10-17 | 2001-07-24 | Laboratoires Msd - Chibret | Ophthalmic composition containing a carbonic anhydrase inhibitor and xanthan gum |
USRE43372E1 (en) | 1999-03-05 | 2012-05-08 | Duke University | C16 unsaturated FP-selective prostaglandins analogs |
US8906962B2 (en) | 2000-03-31 | 2014-12-09 | Duke University | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US9675539B2 (en) | 2000-03-31 | 2017-06-13 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US9579270B2 (en) | 2000-03-31 | 2017-02-28 | Duke University | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US9346837B2 (en) | 2000-03-31 | 2016-05-24 | Duke University | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
WO2001085169A2 (en) * | 2000-05-10 | 2001-11-15 | Alcon, Inc. | R-eliprodil for treating glaucoma |
WO2001085169A3 (en) * | 2000-05-10 | 2002-03-28 | Alcon Universal Ltd | R-eliprodil for treating glaucoma |
JP2004528369A (en) * | 2001-05-03 | 2004-09-16 | アラーガン、インコーポレイテッド | Compositions with improved pharmacokinetic properties |
US9750751B2 (en) | 2004-04-30 | 2017-09-05 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US9669039B2 (en) | 2004-04-30 | 2017-06-06 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US10864218B2 (en) | 2004-04-30 | 2020-12-15 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US10406168B2 (en) | 2004-04-30 | 2019-09-10 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US9101583B2 (en) | 2004-04-30 | 2015-08-11 | Allergan, Inc. | Microparticles manufactured in an oil-in-water process comprising a prostamide |
US9326949B2 (en) | 2004-04-30 | 2016-05-03 | Allergan, Inc. | Method of making oil-in-oil emulsified polymeric implants containing a hypotensive lipid |
US10398707B2 (en) | 2004-04-30 | 2019-09-03 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
US9393223B2 (en) | 2004-04-30 | 2016-07-19 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US10328086B2 (en) | 2004-04-30 | 2019-06-25 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US8900622B1 (en) | 2004-04-30 | 2014-12-02 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US10064872B2 (en) | 2004-04-30 | 2018-09-04 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
US9707238B2 (en) | 2004-04-30 | 2017-07-18 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
WO2005110424A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Biodegradable intraocular implants containing prostamides |
US9775846B2 (en) | 2004-04-30 | 2017-10-03 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
US7939511B2 (en) | 2004-09-28 | 2011-05-10 | Senju Pharmaceutical Co., Ltd. | Ophthalmic composition containing xanthan gum and amino acid |
US8450295B2 (en) | 2004-09-28 | 2013-05-28 | Senju Pharmaceutical Co., Ltd. | Ophthalmic composition containing xanthan gum and amino acid |
US7998942B2 (en) | 2005-07-11 | 2011-08-16 | Senju Pharamaceutical Co., Ltd. | Eye drop preparation comprising xanthan gum and terpenoid |
US7875271B2 (en) | 2006-03-23 | 2011-01-25 | Senju Pharmaceutical Co., Ltd. | Ophthalmic composition comprising xanthan gum and glucose |
US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
Also Published As
Publication number | Publication date |
---|---|
EP1100491A1 (en) | 2001-05-23 |
CA2337349A1 (en) | 2000-02-03 |
AU5114499A (en) | 2000-02-14 |
JP2002521333A (en) | 2002-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000004898A1 (en) | Ophthalmic compositions for treating ocular hypertension | |
EP0308135B1 (en) | Ocular hypotensive agents | |
EP1100491A1 (en) | Ophthalmic compositions for treating ocular hypertension | |
US5194429A (en) | Ocular hypotensive agents | |
Hellberg et al. | Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist | |
EP0580268B1 (en) | Ocular hypotensive agents | |
EP0998277A1 (en) | Ophthalmic compositions for treating ocular hypertension | |
US20020094981A1 (en) | Ophthalmic compositions for treating ocular hypertension | |
US6545045B1 (en) | Prostaglandin E agonists for treatment of glaucoma | |
EP1267847B1 (en) | 5ht 2 agonists for controlling iop and treating glaucoma | |
US7129272B2 (en) | Apoptosis inhibitor | |
US6232343B1 (en) | Ophthalmic preparations | |
US5405846A (en) | Treatment of ocular hypertension with a synergistic combination | |
US5236907A (en) | Ocular hypotensive agents | |
JP4300347B2 (en) | Glaucoma treatment agent consisting of bunazosin and prostaglandins | |
US20050043412A1 (en) | Remedies for glaucoma comprising bunazosin and prostaglandins | |
US20060211700A1 (en) | (R)-8,9-dichloro-2,3,4,4a-tetrahydro-1H,6H-pyrazino[1,2-a]quinoxalin-5-one for controlling IOP and treating glaucoma | |
EP0795331B1 (en) | Ocular depressor | |
JP5011548B2 (en) | Pharmaceutical composition for the treatment of ocular hypertension or glaucoma | |
US6927233B1 (en) | 5ht2 agonists for controlling IOP and treating glaucoma | |
US6420422B1 (en) | Ocular hypotensive agents | |
JP2592196B2 (en) | Choroidal blood flow increase agent | |
JP2002501017A (en) | Method for increasing oxygen tension in the optic nerve and retina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2337349 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 560892 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999935726 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 51144/99 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1999935726 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999935726 Country of ref document: EP |